Thomas Bell, DO
Internal Medicine · Greensboro, NCNPI 1801248810
Payments from drug & device makers
Across 254 payments — averaging $114.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$25K
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$575
- OPKO Pharmaceuticals, LLC$362
- Amgen$296
- Boehringer Ingelheim$191
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$23,41581%
- Travel & lodging$3381%
- Food & beverage$4,73416%
- Education$4852%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 59 | $24,878 |
| AstraZeneca | 48 | $1,044 |
| Otsuka America Pharmaceutical, Inc. | 28 | $575 |
| OPKO Pharmaceuticals, LLC | 19 | $362 |
| Amgen(2 entities) | 13 | $296 |
| Boehringer Ingelheim | 10 | $191 |
| Travere Therapeutics, Inc. | 10 | $181 |
| Novartis | 7 | $177 |
| Aurinia Pharma U.S., Inc. | 8 | $174 |
| Vifor Pharma, Inc. | 7 | $159 |
| Mallinckrodt Hospital Products Inc. | 8 | $157 |
| Fresenius USA Marketing, Inc. | 7 | $149 |
| ANI Pharmaceuticals, Inc. | 6 | $130 |
| Daiichi Sankyo Inc. | 6 | $128 |
| GSK | 6 | $122 |
| Ardelyx, Inc. | 3 | $71 |
| Akebia Therapeutics Inc | 3 | $65 |
| Calliditas Therapeutics US Inc. | 3 | $58 |
| Exact Sciences | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$23,753
How this compares
$28,972 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 49 | $91,561 |
| FarxigaDapagliflozin Propanediol | 106 | $76,590 |
| AuryxiaFerric Citrate | 27 | $35,510 |
| KerendiaFinerenone | 41 | $26,235 |
| RayaldeeCalcifediol | 12 | $14,149 |
| JardianceEmpagliflozin | 21 | $12,005 |
| Sevelamer Carbonate | 53 | $5,308 |
| Losartan Potassium | 189 | $1,038 |
| Torsemide | 59 | $685 |
| Cinacalcet Hcl | 13 | $515 |
| Potassium Chloride | 42 | $504 |
| Bumetanide | 26 | $463 |
| Hydralazine Hcl | 62 | $418 |
| Furosemide | 111 | $365 |
| Carvedilol | 68 | $297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $149 | $91,56149 claims |
| AstraZenecaFarxiga | $1,044 | $76,590106 claims |
| Akebia Therapeutics IncAuryxia | $65 | $35,51027 claims |
| BayerKerendia | $24,878 | $26,23541 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $362 | $14,14912 claims |
| Boehringer IngelheimJardiance | $191 | $12,00521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Greensboro
- Keung LeeGreensboro$5.1M
- Walter PharrGreensboro$2.3M
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.